Combination of PD‐1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second‐line therapy for relapsed/refractory classical Hodgkin lymphoma. (7th October 2021)

• Record Type: Journal Article
• Authors: Zhang, Yu‐Chen; Wang, Jin‐Ni; Ma, Shu‐Yun; Cai, Jun; Su, Ning; Huang, Hui‐Qiang; Li, Zhi‐Ming; Xia, Zhong‐Jun; Huang, He; Liu, Pan‐Pan; Xia, Yi; Cai, Qing-Qing
• Is Part Of: British journal of haematology. Volume 196:Number 1(2022)
• Page Start: 127
• Page End: 135
• Publication Date: 2021-10-07
• Subjects: classical Hodgkin lymphoma -- relapsed or refractory -- second‐line -- PD‐1 -- combined therapy; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.17849
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Patients with classical Hodgkin lymphoma (cHL) who do not achieve complete remission (CR) after second‐line chemotherapy have poor clinical outcomes. Besides, conventional salvage chemotherapy regimens have an unsatisfactory CR rate. The present retrospective study reports the efficacy and toxicity of the GVD (gemcitabine, vinorelbine, liposomal doxorubicin) regimen with or without programmed cell death 1 (PD‐1) inhibitor for patients with cHL who failed first‐line treatment. A total of 103 patients with cHL (GVD+PD‐1 group, n = 27; GVD group, n = 76) with response assessment based on positron emission tomography were included. The GVD+PD‐1 group tended to have a higher CR rate than GVD group (85·2% vs. 65·8%, P = 0·057) and had a better event‐free survival (EFS) ( P = 0·034). Subgroup analysis showed that patients with low‐risk second‐line International Prognostic Score might benefit from the addition of PD‐1 inhibitor (GVD+PD‐1 vs. GVD, 100·0% vs. 64·7%, P = 0·028) and had better EFS than GVD alone ( P = 0·016). Further analysis demonstrated that PD‐1 consolidation therapy might provide an EFS benefit ( P = 0·007). The toxicity of the GVD+PD‐1 regimen was comparable to the GVD regimen, except for higher rates of hypothyroidism and autoimmune pneumonitis, which were manageable. In conclusion, combining a PD‐1 inhibitor with a GVD regimen could be a potentially effective second‐line therapy for patients with cHL.